Heidi Overton Faces Senate Pressure Over FDA Independence And Advisory Committee Cuts

Heidi Overton’s nomination hearing for FDA commissioner turned into a broader argument about whether the agency can operate independently under President Donald Trump. Members of the Senate Health, Education, Labor, and Pensions Committee repeatedly asked the 37-year-old physician and current White House advisor whether she would stand up to the president when public-health decisions clash with political directives.

The sharpest criticism came from committee chair Bill Cassidy and ranking member Bernie Sanders, who framed the issue around trust. Cassidy said Health Secretary Robert F. Kennedy, Jr. had made commitments to him during a Jan. 2025 hearing and later said he had to follow what the president told him to do. Cassidy told Overton the committee needed to know whether she would be “radically honest” and use her authority to defend sound science and children’s health.

That framing made the hearing less about conventional management questions and more about whether the commissioner’s office can still serve as a scientific counterweight inside the Trump administration. For regulated industries, that distinction matters because uncertainty at the top of the FDA can affect how companies read policy durability, advisory processes and enforcement consistency.

The flashpoints

Senators returned often to an August event where Overton stood behind Trump as he signed an executive order saying the combined measles, mumps and rubella vaccine should be split into three single-disease shots, which are not currently approved in the U.S. Cassidy asked whether the current combined MMR vaccine was safe and effective. Overton answered that it is licensed and approved by the FDA, is safe and effective, and is the best tool right now in the public health response to the measles outbreak.

Ed Markey said she failed to correct Trump at that signing when he suggested the MMR vaccine could be lethal. Overton responded that the current vaccine is safe and effective, while adding that she believes the president is responding to demand for additional options. Sanders cited her role in advancing the administration’s agenda as a reason for having serious concerns about the nomination.

Mifepristone was another recurring line of attack, though from both directions. Democratic members said her statements that the drug is safe and effective did not go far enough, while Republicans pressed for stronger criticism of its continued availability or of the current Risk Evaluation and Mitigation Strategy attached to it.

Flavored vapes also emerged as a test of independence. Susan Collins referenced former FDA Commissioner Marty Makary’s resignation in May after he took a stand against fruit-flavored vapes and was, in her words, “apparently overruled.” Overton said there is “100% agreement from this administration that we must protect kids from illegal substances and from vapes and from flavored vapes.”

Advisory committees and agency process

Chris Murphy used the hearing to focus on advisory committees, which he said have been scaled back since the beginning of Trump’s second term in January 2025. Murphy said 27% of all advisory boards have been eliminated and that the remaining groups have held 72% fewer meetings.

He asked Overton to commit to restarting the advisory committees that had been disbanded under the president. Overton said that if she is confirmed as FDA commissioner, advisory committees will meet at the FDA. She did not, however, commit to Murphy’s standard of ruling out any further shutdowns.

That answer matters because advisory committees are one of the clearest signals of how transparent and consultative the FDA intends to be. A return to more regular meetings would continue a shift already seen under interim FDA commissioner Kyle Diamantas, including meetings on Capricor Therapeutics’ deramiocel and Replimune’s RP1.

The road here

Before the hearing, Overton received backing from former commissioners Scott Gottlieb and Mark B. McClellan in a STAT opinion piece. If confirmed, she would be the youngest FDA commissioner ever at 37.

The hearing showed that her confirmation case is likely to turn on whether senators believe her public assurances can translate into operational independence. She gave direct support for the safety and effectiveness of the currently approved MMR vaccine and promised advisory committees will meet. What she did not fully resolve is how often she would oppose the White House publicly when those positions are tested in practice.